Advanced in Multiple Myeloma

Dr. John Hausdorff

Montage Medical Group
Monterey, CA
Advanced
in Multiple Myeloma
Specialties:Palliative Medicine | Oncology | Hematology Oncology
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

John Hausdorff is a Palliative Medicine specialist and an Oncologist in Monterey, California. Dr. Hausdorff and is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Colorectal Cancer, Lynch Syndrome, Familial Colorectal Cancer, and Childhood Iron Deficiency Anemia.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Multiple Myeloma.

Specialties
Palliative Medicine
Oncology
Hematology Oncology
Licenses
Pediatrics in CA
Hospital Affiliations
Community Hospital Of The Monterey Peninsula
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield

Locations

MONTAGE MEDICAL GROUP
23845 Holman Hwy, Suite 210, Monterey, CA 93940
831-620-0700
Other Locations
MONTEREY BAY ONCOLOGY A MEDICAL CORPORATION
5 Harris Ct, Bldg T, Monterey, CA 93940
831-375-4105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 02, 2024
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

3 Total Publications

Getting by with a Little Help from Our Friends.
Getting by with a Little Help from Our Friends.
Journal: Journal of palliative medicine
Published: April 02, 2021
Similar Doctors
Expertise in
6
conditions
Dr. Deepu Madduri
Hematology | Hematology Oncology | Oncology
Expertise in
6
conditions
Dr. Deepu Madduri
Hematology | Hematology Oncology | Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (60.9 mi)
650-723-4000
Languages Spoken:
English

Deepu Madduri is a Hematologist and a Hematologist Oncology provider in Stanford, California. Dr. Madduri and is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Surbhi Sidana
Expertise in
9
conditions
Dr. Surbhi Sidana
Hematology | Oncology | Hematology Oncology
Expertise in
9
conditions
Dr. Surbhi Sidana
Hematology | Oncology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (60.9 mi)
650-723-4000
Experience:
14+ years
Languages Spoken:
English
Offers Telehealth

Surbhi Sidana is a Hematologist and an Oncologist in Stanford, California. Dr. Sidana has been practicing medicine for over 14 years and is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. Her top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Thyroidectomy.

Michaela Liedtke
Expertise in
21
conditions
Dr. Michaela Liedtke
Hematology | Oncology
Expertise in
21
conditions
Dr. Michaela Liedtke
Hematology | Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (60.9 mi)
650-723-4000
Languages Spoken:
English
Offers Telehealth

Michaela Liedtke is a Hematologist and an Oncologist in Stanford, California. Dr. Liedtke and is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. Her top areas of expertise are Primary Amyloidosis, Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile